{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:31Z","timestamp":1792027351321,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijantimicag.2013.06.006","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T05:20:36Z","timestamp":1374729636000},"page":"250-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections"],"prefix":"10.1016","volume":"42","author":[{"given":"Antonello","family":"Di Paolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Polillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet I.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2013.06.006_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1358\/dot.2009.45.1.1315922","article-title":"Future trends in the treatment of serious Gram-positive infections","volume":"45","author":"Metzger","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijantimicag.2008.12.007","article-title":"Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcome Registry and Experience (CORE)","volume":"33","author":"Mohr","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0025","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0030","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijantimicag.2011.03.006","article-title":"Daptomycin: evaluation of a high-dose treatment strategy","volume":"38","author":"Wu","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e31820fc8e1","article-title":"Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10mg\/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections","volume":"30","author":"Abdel-Rahman","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0050","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.01774-10","article-title":"Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA\/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin","volume":"55","author":"Tascini","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0055","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.00059-07","article-title":"Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0060","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.01741-10","article-title":"Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections","volume":"55","author":"Kullar","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/AAC.01608-12","article-title":"Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis","volume":"57","author":"Tascini","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0070","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","article-title":"Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever","volume":"53","author":"Bubalo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0b013e3181d3f5cb","article-title":"A rapid liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma","volume":"32","author":"Polillo","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0085","series-title":"NONMEM users guides","author":"Beal","year":"1989"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1469-0691.2006.01455.x","article-title":"EUCAST technical note on daptomycin","volume":"12","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0115","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2009.09.012","article-title":"Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience","volume":"31","author":"Sakoulas","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0120","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1128\/AAC.01321-07","article-title":"Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury","volume":"52","author":"Mohr","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","article-title":"Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis","volume":"39","author":"Vilay","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0130","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1345\/aph.1P745","article-title":"TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient","volume":"45","author":"Pea","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0135","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.coph.2010.06.006","article-title":"Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus","volume":"10","author":"Nannini","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0140","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints\u2014bacteria (v. 3.1). http:\/\/www.eucast.org\/clinical_breakpoints [accessed December 2011]."},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0145","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkp069","article-title":"Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype","volume":"63","author":"Begic","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.06.006_bib0150","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T02:12:46Z","timestamp":1646187166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0924857913002136"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.06.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}